Clinical pathology – Vet Clin Path Journal Fri, 04 Jun 2021 06:09:21 +0000 en-US hourly 1 Clinical pathology – Vet Clin Path Journal 32 32 NSW spearheads key COVID-19 vaccine research Fri, 04 Jun 2021 05:48:53 +0000

A leading group of experts in New South Wales will launch Australia’s first research to inform vaccine policy in the state and beyond.

The Collaborative Research Group on Vaccines, Infections and Immunology (VIIM) will receive more than $ 4.5 million in NSW government funding over three years to study clinical and immunological responses to COVID-19 vaccines in NSW beneficiaries.

VIIM brings together the leading researchers and practitioners in vaccines, infections and immunology in New South Wales. It integrates the expertise of two universities, four medical research institutes, the statewide pathology service, adult and pediatric health services and the National Center for Immunization Research and Surveillance.

NSW Director of Health Dr Kerry Chant said the program will strengthen our knowledge of COVID-19 vaccines, including their effectiveness against variant strains of the virus in the years to come.

“With the vaccine rollout now well underway, this real-world surveillance and research will continue to provide us with timely and robust data to ensure the best outcomes for the people of NSW and help us chart the way forward,” Dr Chant said. .

“This puts us in a strong position and will inform a vaccine policy that can address emerging issues and opportunities, as well as future development and testing of next-generation vaccines.

“We continue to learn throughout this pandemic and this research will allow us to advise on immunization schedules, including the potential need for booster vaccines for vulnerable groups and the wider community.”

Dr Chant said NSW is in a unique position to enrich the global body of knowledge on vaccines and immunity, as the majority of our population has not been exposed to COVID-19, unlike many other countries. .

“This research will also establish an invaluable biobank of specimens that will be crucial for current and future research to keep the people of NSW healthy and protected from infectious disease,” said Dr Chant.

VIIM’s experts in vaccines, infections and immunity are from the Western Sydney Local Health District, Sydney Local Health District, Sydney Children’s Hospital Network, NSW Health Pathology, National Center for Immunization Research and Surveillance, University of Sydney’s Marie Bashir Institute, University of NSW, Westmead Institute of Medical Research, Centenary Institute and Kirby Institute.

The grant is part of the $ 25 million COVID-19 priority research fund previously announced by the state.

/ Public distribution. This material is from the original organization and may be ad hoc in nature, edited for clarity, style and length. View full here.

Source link

]]> 0
Seattle Cancer Care Alliance (SCCA) clinicians’ clinical oncology results to be presented at ASCO’s annual meeting in 2021 Thu, 03 Jun 2021 11:00:00 +0000

SEATTLE – (COMMERCIAL THREAD) –Seattle Cancer Care Alliance (SCCA) today announced presentations from the organization’s clinicians to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting from June 4 to 8, 2021.

SCCA clinicians have contributed to studies of several types of cancer spanning the entire continuum of cancer care – from prevention to diagnosis to treatment. Presentations will highlight results from Phase 1 trials, CAR T therapy, breast cancer, bladder cancer, non-small cell lung cancer and hematologic cancers. In addition, there are numerous studies on the impact of the COVID-19 pandemic on cancer diagnosis, clinical care and clinical trials in oncology. SCCA clinical researchers have also contributed to new findings related to genetic profiling, prostate needle biopsy pathology, and precision therapy for salivary gland cancer.

“The SCCA is a leader in groundbreaking clinical trials turning scientific discoveries into exciting new treatments that often change the way cancer care is delivered,” said Nancy Davidson, MD, president and executive director of the Seattle Cancer Care Alliance and former president of ASCO. “The work presented by our physician-researchers at ASCO 2021 once again demonstrates these ongoing efforts to improve the way patients are treated and advance multidisciplinary cancer care. ”

More information on SCCA presentations and publications at ASCO is available at:

Presentation details:

Breast cancer screening in carriers of the pathogenic variants ATM, CHEK2 and PALB2: a comparative modeling analysis.

Abstract: 10500

Author of SCCA: Kathryn P. Lowry, MD

Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: estimates from collaborative simulation modeling.

Abstract: 6562

Author of SCCA: Kathryn P. Lowry, MD

Adoptive immunotherapy phase I study for advanced MUC1 * positive breast cancer with autologous T cells designed to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1 *).

Abstract: TPS2663

Author of SCCA: Jennifer M. Specht, MD and David G. Maloney, MD, PhD

The efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR + / estrogen receptor (ER) + breast cancer in a clinical study international phase 2.

Abstract: 1020

Author of SCCA: Hannah M. Linden, MD

AMEERA-1: Phase 1/2 study of amenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER + / factor receptor Human epidermal growth 2-negative (HER2-) metastatic breast cancer (mBC).

Abstract: 1058

Author of SCCA: Hannah M. Linden, MD

Case-Based Panel: Optimizing Precision Therapy in Salivary Gland Cancers with a Look to the Future

SCCA speaker: Cristina P. Rodriguez, MD

PrE0807: A phase Ib feasibility study of neoadjuvant nivolumab (N) without or with lirilumab (L) in patients ineligible for cisplatin (pts) with muscular invasive bladder cancer (MCDI).

Abstract: 4518

Author of SCCA: Petros Grivas, MD, Ph.D.

Maintenance first-line (1L) Avelumab plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line treatment in JAVELIN Bladder 100.

Abstract: 4525

Author of SCCA: Petros Grivas, MD, Ph.D.

Fluciclovine PET / CT (FACBC) in Oligometastatic Prostate Cancer (Flu-BLAST-PC).

Abstract: TPS5099

Author of SCCA: Risa L. Wong, Jonathan L. Wright, MD, MS, Heather H. Cheng, MD, PhD and Evan Y. Yu, MD

Clinical accuracy of information extracted from prostate biopsy pathology reports using natural language processing.

Abstract: 1557

Author of SCCA: Risa L. Wong and John L. Gore, MD, MS, FACS

Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: a comprehensive genomic profiling study (CGP).

Abstract: 3130

Author of SCCA: Petros Grivas, MD, Ph.D.

Concordance of DNA damage repair (DDR) gene mutations in matched primary and metastatic prostate cancer (PC) samples.

Abstract: 5020

Author of SCCA: Michael T. Schweizer, MD, Evan Y. Yu, MD and Colin C. Pritchard, MD, PhD

Case-based panel: Optimizing the management of urothelial cancer from organ-confined disease to metastatic disease: a multidisciplinary approach

SCCA Moderator / President: Evan Y. Yu, MD

Oral session: Germline genetic testing for prostate cancer

Discussing the SCCA: Colin C. Pritchard, MD, PhD

The product type CD19 CAR T-cell has an independent impact on the severity of CRS and ICANS in patients with aggressive NHL.

Abstract: 7532

Author of SCCA: Jordan Gauthier, MD, M.Sc., Mazyar Shadman, MD, MPH, David G. Maloney, MD, PhD and Cameron J. Turtle, MBBS, PhD, FRACP, FRCPA

Efficacy of clinical breast examination in women surviving irradiated thorax from childhood Hodgkin lymphoma (HL).

Abstract: 10028

Author of SCCA: Janie M. Lee, MD, M.Sc.

Demographics, Outcomes, and Risk Factors for Patients (Pts) with Sarcoma and COVID-19: A Multi-Institutional Cohort Analysis.

Abstract: 11523

Author of SCCA: Michael J. Wagner, MD

Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after more than five years of follow-up.

Abstract: 9517

Author of SCCA: Paul Nghiem, MD, PhD

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in non-small cell lung cancer (NSCLC) resistant to EGFR inhibitors and mutated to EGFR (EGFRm).

Abstract: 9007

Author of SCCA: Christina S. Baik, MD, MPH

Oral session: Emerging trends in radiation for localized lung cancers

SCCA speaker: Ramesh Rengan, MD, Ph.D.

Phase 1b dose escalation study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of GS-3583, an Fc agonist FLT3 fusion protein, in patients with advanced solid tumors.

Abstract: TPS3147

Author of SCCA: John A. Thompson, MD

First phase I / II human study of CYT-0851, a first-class inhibitor of homologous recombination mediated by RAD51 in patients with advanced solid and hematologic cancers.

Abstract: 3006

Author of SCCA: Ryan C. Lynch, MD

Training session: COG perspective on the impact of COVID-19 on pediatric oncology clinical trials and their implications for the future

SCCA speaker: Douglas S. Hawkins, MD

Discussion poster session: COVID-19 and cancer: learning as you go

SCCA speaker: Petros Grivas, MD, Ph.D.

Cancer Diagnosis and Adverse Financial Events: Evidence from Credit Reports.

Abstract: 6504

Author of SCCA: Veena Shankaran, MD, MS

Choosing Wisely: Selecting the Right Population at the Right Time for DNA Damaging Therapy

SCCA speaker: Elizabeth M. Swisher, MD

About Seattle Cancer Care Alliance

The Seattle Cancer Care Alliance brings together leading cancer research teams and specialists from Fred Hutch, Seattle Children’s and UW Medicine – an extraordinary group whose sole purpose is the pursuit of better, longer and richer lives for our patients. . Based in Seattle’s South Lake Union neighborhood, the Seattle Cancer Care Alliance has nine clinical care sites in the region, including a medical oncology clinic at EvergreenHealth in Kirkland; hematology / medical oncology and infusion services at Overlake Medical Center in Bellevue, medical and radiation oncology clinics at UW Medical Center – Northwest Seattle and medical oncology services at SCCA Issaquah, as well as network affiliations with hospitals in five states. For more information on SCCA, visit

Source link

]]> 0
IDSA issues guidelines for SARS-CoV-2 antigen testing Wed, 02 Jun 2021 18:32:27 +0000 Subscribe We have not been able to …]]>

Hanson does not report any relevant financial disclosure.

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact

The Infectious Diseases Society of America has published new guidelines for the use of SARS-CoV-2 antigen tests.

“Antigen tests have really become more and more available during the pandemic and have helped us meet the need for more universal and faster access to diagnostic tests for SARS-CoV-2” Kimberly E. Hanson, MD, MHS, associate professor of internal medicine and assistant associate professor of pathology at the University of Utah School of Medicine, said at an IDSA news briefing. “These tests can be used in a variety of contexts. “

IDSA antigen test

Source: IDSA. IDSA diagnostic guidelines for COVID-19: antigen testing. Accessed June 2, 2021.

the advice was based on a systematic review of the literature by infectious disease clinicians and clinical microbiologists, which found that clinical performance data on rapid antigenic tests that have received emergency use clearance from the FDA are “primarily limited to a single point test compared to standard nucleic acid amplification test (NAAT) as a gold standard,” the guidelines panel wrote.

“Rapid antigenic tests have high specificity and low to modest sensitivity compared to standard NAAT methods. The sensitivity of the antigen test is highly dependent on viral load, with differences observed between symptomatic versus asymptomatic individuals and the time of testing after symptom onset, ”the panel wrote.

“Based on these observations, rapid RT-PCR or laboratory NAAT remain the diagnostic methods of choice for diagnosing SARS-CoV-2 infection,” the panel continued. “However, when molecular tests are not readily available or are logistically impractical, antigen testing can help identify some people infected with SARS-CoV-2.”

The guide, which was based on evidence categorized as “very low to moderate,” includes five diagnostic recommendations:

  • People with suspected symptoms of COVID-19 should be tested using NAAT (either rapid RT-PCR or laboratory NAAT) versus antigen testing.
  • Asymptomatic individuals at risk of exposure to SARS-CoV-2 should be tested via a single standard NAAT (either rapid RT-PCR or laboratory NAAT) versus a single rapid antigen test.
  • Asymptomatic individuals at risk of exposure to SARS-CoV-2 should receive a single standard NAAT (either rapid RT-PCR or laboratory NAAT) rather than two consecutive rapid antigen tests.
  • The panel does not recommend for or against rapid single antigen testing as opposed to not testing asymptomatic people at risk of exposure to SARS-CoV-2.
  • The IDSA does not advocate for or against the use of repeated rapid antigenic testing rather than not testing asymptomatic people at risk of exposure to SARS-CoV-2.

“When we reviewed the literature and made our recommendations and suggestions, this was a time when highly effective vaccines were not widely available and there was no significant coverage of the vaccinated adult population,” said Hanson . “It is likely that the role of testing will change as we see increased vaccine coverage in the population and the prevalence of infection in communities begins to decline – which we are already starting to see. “

The IDSA said the guidelines were approved by the American Society for Microbiology, the Society for Healthcare Epidemiology of America and the Pediatric Infectious Diseases Society.

Source link

]]> 0
The players in the veterinary reference laboratories market will make profitable investments during the period 2021-2026 Wed, 02 Jun 2021 00:44:53 +0000

The last Reference veterinary laboratory market The research report incorporates an easily understandable understanding of the factors that will drive and hinder the growth of the industry in the years to come. Further, it lists the different opportunities in different geographies and other submarkets followed by an in-depth look at the competitive landscape.

According to experts, the industry is expected to grow significantly throughout 2021-2026, registering a CAGR of XX%.

Speaking of the latest updates, in addition to covering recent mergers, acquisitions and partnerships of the top contenders, the research literature highlights the impact of Covid-19 and how it has changed the business scenario. While some companies have adapted well to the pandemic, many continue to face challenges. With this in mind, our comprehensive analysis mentions strategies and opportunities to help companies generate strong returns in the near future.

Request a sample copy of this report @

Key Features of the Veterinary Reference Laboratory Market report:

  • Impact of Covid-19 on the industry’s growth model
  • Records of sales volume, net income and market size.
  • Main industry trends
  • Business expansion opportunities
  • Growth rate forecasts for the market
  • Advantages and disadvantages of using direct and indirect sales channels
  • Leading distributors, resellers and traders

Veterinary Reference Laboratories Market Segments Covered In The Report:

Geographic fragmentation: North America, Europe, Asia-Pacific, South America and the Middle East and Africa.

  • Market analysis at national and regional level
  • Sales achieved, returns collected and shares captured by each regional market
  • Predictions of revenue and growth rate for each region over the stipulated period

Types of products: Dogs, Cats, Horses, Cattle, Pigs, Poultry and others

  • Price models for each product category.
  • Approximations of market shares based on sales and profits gained by each product segment

Range of applications: clinical pathology, bacteriology, virology, parasitology, productivity tests, pregnancy tests, toxicology tests and others

  • Product pricing based on scope of application
  • Sales and revenue estimates for each type of application over the duration of the forecast

Competitive Dashboard: IDEXX Laboratories, Inc., VCA, Inc., GD Animal Health, Boehringer Ingelheim, Zoetis, Inc., Neogen Corporation, Laboklin GmbH, Synlab International GmbH, Marshfield Labs, Texas A&M Veterinary Medical Diagnostic Laboratory, University of Minnesota (Veterinary Diagnostic Laboratory), Iowa State University (Veterinary Diagnostic Laboratory), Protatek International Inc., Animal and Plant Health Agency, Animal Health Diagnostic Center (Cornell University), National Veterinary Services Laboratory Usda-Aphis, Znlabs, Colorado State University (Veterinary diagnostics) Laboratories), The Pirbright Institute and Friedrich-Loeffler-Institut (FLI

  • Activity synopsis of listed companies
  • Range of products and services of the main players
  • Sales, price, revenue, gross margin and market share figures for each major market
  • SWOT analysis of large companies
  • Analysis of industry concentration ratio and commercialization rate
  • Review of popular business tactics exercised by large companies

Important features found in Offer Highlights and Key Report:

  • Detailed overview of veterinary reference laboratory market trends
  • Changing industry market dynamics
  • In-depth market segmentation by type, application etc.
  • Historical, Current and Projected Veterinary Reference Laboratory market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive Landscape for Veterinary Reference Laboratories Market Share
  • Strategies of the main players and product offerings
  • Potential and niche segments / regions showing promising growth

Request a customization of this report @

Source link

]]> 0
Credent’s new technological solution will be a game-changer in healthcare Mon, 31 May 2021 13:31:28 +0000

During the pandemic, the diagnostics industry faced many challenges. From logistics to phlebotomists and technicians to technology, the diagnostic industry depends on different vendors to provide phlebotomists, logistics, lab technicians, technology and other services.

Established in 2012 with the vision to become the leading healthcare logistics company in India, Credent is one of the leading partners for home sample collection and pathology based workforce solutions in the diagnostic industry. With advancements in technology, they launched smart app and became the first and only company to provide complete solution to major diagnostic companies in India.

Explaining how the application has evolved digitally, Tarun Sharma, Director of Credent Group, said: “Our application will remove the outsourcing technology to keep up with all logistics solutions, home collection solutions and hand solutions. -work. With the launch of this app, Credent will become the first company in India to offer a complete solution under one roof for the diagnostics industry. “

Credent is the answer to all diagnostic needs

Strengthened by its association with various diagnostic and healthcare companies in India as well as many other organizations, Credent has established its worthy presence in over 164 cities across India with over 2,800 professionals.

Credent offers pre-analytical services from sample selection to sample delivery to the laboratory due to their strong network. With 20+ Air Connectivity, 5+ OTC Route Connectivity, 6 Vans, and over 1,284 Field Executives with bikes, they provide services nationwide. By 2025, they plan to integrate and train a staff of more than 5,000 people and expand their workspace in more than 300 cities.

Credent has become Game Changer in the industry by offering all of these services under one roof:

1. Home collection services

With a team of 807 home collection phlebotomists. Credent offers door-to-door collection services to a large extent across the length and breadth of India. They have an established presence in major cities in every state of India.

Their home collection service provides collection of blood / urine samples for laboratory analysis. This service is available to people who may not have time to visit a laboratory or to patients who cannot travel because they are sick or bedridden. Samples collected are tested and analyzed in associated laboratories to ensure accurate test results. They also offer home collection services to hospitals and laboratories to improve their services and help them attract more customers.

2. Phlebotomist services

Credent has a team of over 700 phlebotomists and the number is increasing in cities large and small in India. Their phlebotomists are trained to expertly collect blood samples with minimal patient discomfort, and then store those samples in temperature-controlled packaging. They are also experts in observing the patient during the process and in providing assistance that may be required in the event of an adverse reaction. They take care of the collected samples, packaging and shipping procedures with documentation if they are in the field. They are also trained in new technical standards and tests as well as new NABL guidelines. You can employ these trained phlebotomists or, if you plan to recruit people, they can train them to improve their skill levels.

3. Outsourcing of the workforce

Credent specializes in providing contract, one-off and temporary labor with a focus on research institutions, pharmaceuticals, hospitals, and laboratory segments for clinical trials and corporate health checks. . They assure their clients that those recommended for temporary positions get to work immediately. Outsourcing their manpower needs saves them time and money in addition to doing the job much better.

4. Cold chain logistics

They have standardized cold chain logistics procedures to comply with international specifications with a detailed system in place that starts with providing the right equipment for collection, storage and transit with a data logger, through to delivery point. All processes are recorded and both sides of the transaction have access to detailed records.

5. Laboratory technician

Credent is a trusted source for highly trained and skilled lab technicians to support the most demanding test procedures. They provide highly trained and skilled lab technicians who will complete tasks in record time and are a real asset to your organization. With Credent here, your lab just keeps running.

6.Customer service setup

We use a dedicated IT infrastructure and multi-channel communications service managed by trained customer service representatives. Customer experience matters a lot these days and can make a difference to your customer. Their customer service setup helps you respond to queries or complaints quickly and resolve them to caller satisfaction.

During the pandemic, phlebotomists played a critical role in collecting and delivering samples. Credent in turn shows their respect and salutes all those individuals and other Corona warriors who have continued to work day and night without worrying about putting themselves in danger.

Credent shows growth in healthcare

Some of the renowned names in the health industry that Credent has confederated include Dr Lal Path Labs, SRL Diagnostics, Apollo, and many more. Their first-rate services and determined teamwork have always ensured smooth functioning between clients.

Faithful to ethics, Credent Group is moving forward on the path to progress. Using cutting-edge technologies, their new application takes the company to new heights. The Credent team places great importance on the confidentiality of customer data and offers fast turnaround times with their one-stop-shop services. They are enriched with a database covering various health care projects. With a PAN India reach, they are determined to serve any corner of the country with the utmost loyalty and dedication from their professionals.

Disclaimer: This is a company press release. No HT reporter was involved in the creation of this content.

Source link

]]> 0
A simple tool predicts the individual risk of Alzheimer’s Sun, 30 May 2021 16:00:42 +0000

A simple blood test, combined with brief memory tests, has shown who will develop Alzheimer’s disease in the future with a high degree of accuracy.

Combining phosphorylated tau plasma (p-tau), APOE genotype, and 10-minute memory and executive function test scores predicted onset of Alzheimer’s disease within 2 to 6 years in people with memory impairment with 90% certainty, Oskar reported Hansson, MD, PhD, and Sebastian Palmqvist, MD, PhD, both at Lund University in Sweden and colleagues.

When dementia experts looked at the same patients, they were about 71% accurate, the researchers noted in Nature medicine.

“We show for the first time that a rapid and cost-effective diagnostic algorithm clearly outperforms the clinical workup typically performed today when it comes to predicting Alzheimer’s dementia,” said Hansson. MedPage today.

To build their prediction algorithms, the researchers studied 340 people with mild cognitive symptoms in Sweden. BioFINDER cohort. Participants were between 60 and 80 years of age, had a baseline Mini Mental Status Examination (MMSE) score of 24 to 30, and did not meet criteria for any dementia. The primary outcome measure was prediction of progression to Alzheimer’s dementia compared to any other dementia, or of not progressing, in 4 years.

The researchers assessed the demographics, APOE4 genotype, cortical thickness, cognitive measures, and plasma and cerebrospinal fluid (CSF) markers, first looking for the best fit, then omitting variables to find simpler algorithms with similar predictive power. They used data from 543 participants in the Alzheimer’s Disease Neuroimaging Initiative. (ADNI) as the validation cohort.

In 4 years, plasma p-tau217 alone predicted Alzheimer’s disease in the BioFINDER cohort with an area under the curve (AUC) of 0.83. Combining p-tau 217 plasma, memory tests, executive function tests and APOE precision increased to 91% (AUC 0.91, 95% CI 0.88-0.95, P<0.001).

In DNAI, this model had a similar AUC (0.90) using p-tau181 plasma instead of p-tau217. In 2 and 6 years, similar models had AUCs of 0.90 to 0.91 in both cohorts. The use of CSF p-tau, amyloid beta, and neurofilament lumen instead of plasma biomarkers did not significantly improve accuracy.

Tau blood phosphorylated biomarkers have great potential in Alzheimer’s disease, said Nicholas Ashton, PhD, of Gothenburg University in Sweden, who was not involved in the study. “They offer an inexpensive and less invasive alternative to understanding what is going on at the molecular level in the brain,” he said. MedPage today.

Blood tests will be useful both for clinicians and for recruiting people into therapeutic trials for drugs specifically targeted for Alzheimer’s disease, Ashton noted.

Both p-tau217 and p-tau181 performed well in this analysis, he added. “There has been some debate about which is superior, but this study shows that – in combination with cognitive testing and genetic testing – it doesn’t matter what type of phospho-tau biomarker you use: they both gave the same. power of prediction. “

The algorithm is under development for clinics without access to advanced diagnostic instruments, Palmqvist said in a statement. “In the future, therefore, the algorithm could make a major difference in the diagnosis of Alzheimer’s disease in primary health care,” he noted.

So far, it has only been tested on patients who have been examined in memory clinics, he added. “We hope that it will also be validated for use in primary health care as well as in developing countries with limited resources.”

Last update May 30, 2021

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s disease, dementia, MS, rare diseases, epilepsy, autism, headaches. head, stroke, Parkinson’s disease, ALS, concussion, CTE, sleep, pain, etc. To pursue


The study was funded with support from the Swedish Research Council, Swedish Alzheimer Foundation, Swedish Brain Foundation, Knut and Alice Wallenberg Foundation, Marianne and Marcus Wallenberg Foundation, Skane University Hospital and ALF funding, as well as Lund University’s MultiPark Multidisciplinary Research.

Researchers reported relationships with Hoffman-La Roche, Geras Solutions, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, CogRx, Fujirebio, AlzeCure, Abcam, Axon, Biogen, JOMDD / Shimadzu, Julius Clinical, Eli Lilly, MagQu, Novartis, Eisai, GE Healthcare, Pfizer, AC Immune and Brain.

Source link

]]> 0

(MENAFN – Mid-East.Info)

Abu Dhabi, United Arab Emirates: Multiple sclerosis patients in the United Arab Emirates and beyond have a new resource to guide them through their MS journey, thanks to a website launched by Cleveland Clinic Abu Dhabi, which is an integral part of Mubadala Health.

Caused by inflammation of the nerves in the brain and spinal cord, multiple sclerosis (MS) can cause vision problems, muscle weakness, numbness, and a variety of other symptoms. Most often diagnosed between the ages of 20 and 40, multiple sclerosis is twice as common in women as in men. While there is no cure yet, the vast majority of cases can be managed with medications that help stop inflammation, control symptoms, and effectively slow the progression of the disease.

“Multiple sclerosis is definitely a growing condition both here in the UAE and around the world. It usually strikes in the prime of life, causing a lot of anxiety and dread. With early diagnosis and the right treatment, most can lead normal lives. I’ve seen some of my patients do amazing things that even someone without a diagnosis could balk at, ” says Dr Anu Jacob, neurologist and director of the multiple sclerosis department at the Cleveland Clinic Abu Dhabi Neurological Institute.

The new website, in English and Arabic, provides patients and their families with practical advice on a range of topics in simple, easy-to-understand language on symptoms, diagnosis, treatment and lifestyle as well as exercise and diet. The site also provides support material and organized external links for doctors and the MS community at large in the UAE.

“The level of care offered to MS patients in the UAE is comparable to some of the best medical destinations in the world. One gap we noticed is that despite the growing community of people affected by MS, the resources and online support available have not kept up. I hope this website serves as a foundation to help patients in the region find unbiased information that can guide their decisions. We believe that empowering patients with knowledge will help them make the right choices in managing their MS. Seeing that they are not alone and participating in the experiences of other MS patients will empower them and inspire them to realize their own potential, ” continues Dr Jacob.

In addition to drugs to stop inflammation, slow progression and stop symptoms of the disease, the team at the Cleveland Clinic Abu Dhabi Neurological Institute offers a holistic approach to the management of patients with multiple sclerosis. . These range from psychological support and smoking cessation programs to physical therapy and exercise counseling.

“The most common form of multiple sclerosis that we see, especially in our younger patients, is what we call ‘relapsing-remitting’, which means that patients periodically experience a flare-up of symptoms. This form of the disease responds well to lifestyle changes which, when given with the right medication, can prolong remission and reduce symptoms – dramatically improving quality of life, ” says Dr. Jacob.

Some of the most visible effects of multiple sclerosis include muscle weakness, loss of balance, and difficulty walking. Regular exercise, including stretching and progressive weight training, helps keep muscles strong and maintain physical function.

Many people think that exercising with MS is difficult, even dangerous. In fact, it is the opposite. The right amount of exercise that improves strength, endurance, balance, and flexibility can be of great help. One piece of advice we always share is not to push too hard. Excessive exertion can sometimes make symptoms worse, so keeping the right pace is essential, ” says Vinodh Ravindran, a certified multiple sclerosis physiotherapist at the Cleveland Clinic Abu Dhabi.

As part of its commitment to raising the standard of care and improving the quality of life for people with MS, the Cleveland Clinic in Abu Dhabi is carrying out ongoing research projects on how certain drugs could be used to improve still the quality of life of patients.

“Multiple sclerosis can be treated extremely well right here in the UAE. Although this is a diagnosis for life, there is a whole host of approaches we can take to limit its impact and allow people to lead normal lives. I always put myself in my patients’ shoes. If I had MS, I would like my condition to be clearly explained to me and to be supported in choosing the right treatment by a team that takes into account all of my circumstances. After that, aside from the occasional hospital visits for treatments and appointments, I wish I could forget about MS and move on with my life with the confidence that my team will be there if I need them. This is what I want for our patients. MS should not define them, ” concludes Dr Jacob.

As part of its World Multiple Sclerosis Day activities this month, the Neurological Institute at the Cleveland Clinic Abu Dhabi also hosted an informative webinar and question-and-answer session on healthy living with MS and the impact of COVID-19 on patients with this disease.

About Cleveland Clinic Abu Dhabi :

Cleveland Clinic Abu Dhabi, which is an integral part of Mubadala Health, is a multi-specialty hospital located on Al Maryah Island in Abu Dhabi, United Arab Emirates. Cleveland Clinic Abu Dhabi is a unique and unprecedented extension of the United States-based Cleveland Clinic model of care, specifically designed to meet a range of complex and critical care requirements unique to the people of Abu Dhabi.

Cleveland Clinic Abu Dhabi has the following institutes: heart and vascular, neurological, digestive diseases, eyes, respiratory, intensive care, surgical subspecialties, medical subspecialties, emergency medicine, anesthesiology, pathology and laboratory medicine, imaging, quality and patient safety and clinical and nursing care. In all, more than 40 medical and surgical specialties are represented at the Cleveland Clinic Abu Dhabi.

The facilities at the Cleveland Clinic Abu Dhabi combine state-of-the-art equipment and world-class service standards. The hospital is a 394-bed facility (expandable to 490), with five clinical floors, three diagnostic and treatment levels, and 13 floors of critical and acute inpatient units. It is a medical facility run by physicians and serviced by physicians certified by the North American / European Council (or equivalent). Cleveland Clinic Abu Dhabi offers patients in the region direct access to the world’s best healthcare providers and the Cleveland Clinic’s unique model of care, reducing their need to travel overseas for treatment.

Cleveland Clinic Abu Dhabi – Al Ain started offering some medical services in December 2017. The facility is located on the campus of Tawam Hospital in Al Ain.

About Mubadala Health :

Mubadala Health is the integrated healthcare network of Mubadala Investment Company. Established in 2021, Mubadala Health operates, manages and develops a portfolio of healthcare assets including: Abu Dhabi Telemedicine Center (ADTC), Amana Healthcare, Capital Health Screening Center (CHSC), Healthpoint, Imperial College London Diabetes Center ( ICLDC) and National Reference Laboratory (LNR). In addition, the Cleveland Clinic Abu Dhabi is an integral part of Mubadala Health. With a vision to transform the regional healthcare landscape, Mubadala Health sets a new benchmark for the healthcare industry in the UAE and the region with its state-of-the-art facilities and world-class caregivers strive to put patients first in its continuum of care. Innovation, research and education are the fundamental pillars of Mubadala Health, supporting the future development of a sustainable health sector in line with the vision of Abu Dhabi and the region.


Legal notices: MENAFN provides information “as is” without any guarantee of any kind. We do not accept any responsibility for the accuracy, content, images, videos, licenses, completeness, legality or reliability of the information contained in this article. If you have any complaints or copyright issues related to this item, please contact the supplier above.

Source link

]]> 0
Arthroscopy can help detect occult pathology in open treatment of ankle fractures Fri, 28 May 2021 19:04:05 +0000 Subscribe We have not been able …]]>

Disclosures: Aziz does not report any relevant financial disclosure.

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact

Adding ankle arthroscopy to open treatment for ankle fractures can be used to detect and treat occult pathology with a low rate of complications, according to the study results.

Hibba Aziz, MD, and colleagues collected patient demographics and clinical history among 84 ankle fracture patients who underwent open reduction and internal fixation with adjunct ankle arthroscopy from August 2010 to October 2019. The researchers noted the preoperative and postoperative diagnoses of each operative report and intra-articular intervention performed during the time of arthroscopy.

The results showed that the addition of ankle arthroscopy detected new diagnoses in 75% of patients, the most common new pathology being osteochondral lesions (41.9%) and posterior malleolus fractures ( 32.6%). In conjunction with the management of the fractures, the researchers found that 34 patients had undergone 40 additional arthroscopic procedures, including partial synovectomy, loose body excision, microfracture, and chondroplasty. The researchers identified complications in 13 patients, the most common being the removal of material (62%).

Hibba Aziz

Hibba Aziz

“As the outcome data suggest, despite anatomical reduction and appropriate treatment, patients often develop chronic pain and post-traumatic degenerative changes in the ankle after sustaining an ankle fracture. We hope our study can shed light on the importance of ankle arthroscopy as an adjunct to the management of ankle fractures, ”Aziz told Healio Orthopedics. “While there is a need for prospective, high-powered, randomized controlled trials to truly prove the effectiveness of the role of ankle arthroscopy in ankle fractures, we hope our study will be a point of reference. departure to show that this support is legitimate and low risk. [and] relatively inexpensive and should be part of our arsenal when caring for patients with ankle fractures. “

Source link

]]> 0
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS ™ Inhibitor (sotorasib) KRASG12C for Use in Advanced Non-Small Cell Lung Cancer Fri, 28 May 2021 17:15:00 +0000

REDWOOD CITY, Calif .– (BUSINESS WIRE) – Guardant Health, Inc. (Nasdaq: GH) announces that the United States Food and Drug Administration (FDA) has approved Guardant360® CDx assay as the first and only liquid biopsy companion diagnostic for profiling tumor mutations, or complete genomic profile, to identify patients with locally advanced or metastatic non-small cell lung cancer who harbor the KRAS Mutation G12C and may benefit from LUMAKRAS ™ (sotorasib), an FDA approved KRASG12C inhibitor developed and manufactured by Amgen.

FDA approval of Guardant360 CDx was based on clinical validation data from the CodeBreaK 100 trial evaluating sotorasib in patients with locally advanced or metastatic NSCLC. Patients identified with the KRAS The G12C mutation using Guardant360 CDx demonstrated an objective response rate consistent with those identified using traditional tissue biomarker assays.

Lung cancer is the leading cause of cancer death in the United States1 and NSCLC accounts for about 84 percent of all lung cancers.2 It is estimated that 66% of patients with NSCLC have advanced or metastatic disease at the time of initial diagnosis,3 and two out of three with lung adenocarcinoma harbor a motor mutation.4 Clinical guidelines recommend full genomic profiling at the time of diagnosis, for all patients with advanced NSCLC, to assess whether they have any of the growing list of actionable and emerging biomarkers with associated treatment options.5-7 KRAS G12C is one of the most common mutations in NSCLC, occurring in 13% of patients, and until now, targeted therapy options approved by the FDA have not existed.4.8

“The approval of LUMAKRAS represents a significant medical breakthrough for patients with advanced non-small cell lung cancer who harbor the KRAS The G12C mutation because it’s the first and only targeted therapy available to them, “said Darryl Sleep, MD, medical director of Amgen and senior vice president of medical affairs.” However, patients cannot benefit from targeted therapies, or personalized treatments, only if they are tested for biomarkers. The current FDA approval of Guardant360 CDx offers a significant development in biomarker testing by providing a high quality blood test option for patients.

“In the CodeBreaK 100 phase 2 clinical trial, which served as the basis for FDA approval, sotorasib demonstrated convincing efficacy and tolerability in patients with KRAS G12C mutated non-small cell lung cancer. This approval represents a historic milestone for patients with this mutation, ”said Vamsidhar Velcheti, MD, director of thoracic oncology at NYU Langone Health Perlmutter Cancer Center. “This new, targeted therapy reinforces once again why comprehensive biomarker testing at the time of diagnosis is essential. Having additional options, including the availability of a blood test option, like the Guardant360 CDx, will help identify patients who might benefit more quickly and guide treatment decisions. ”

“This revolutionary new therapy from Amgen, LUMAKRAS, highlights the importance of incorporating a complete genomic profile into routine clinical practice to ensure that all patients are evaluated for KRAS G12C and the growing list of other workable mutations that can be treated with targeted therapies dramatically improve clinical outcomes, ”said Helmy Eltoukhy, CEO of Guardant Health. “By providing an FDA-approved companion diagnostic that can quickly provide complete results from a simple blood test, clinicians can have greater confidence in using the test, and patients benefit from less invasive and time-consuming testing. shorter waits to see if they are eligible for a targeted test. therapy such as LUMAKRAS. ”

For oncologists, the FDA-approved Guardant360 CDx delivers complete genomic results from a simple seven-day blood test, helping them overcome the limitations of tissue biopsies to quickly obtain clinically relevant information in time to match. patients with optimal personalized treatment. Guardant360 CDx covers all genes recommended by the National Comprehensive Cancer Network, including those most relevant to clinical care and treatment guidelines for NSCLC.

Since its introduction, the Guardant360 test has gained wide acceptance for blood-based complete genomic profiling with over 200 peer-reviewed publications. It has been trusted by over 9,000 oncologists, with over 150,000 tests performed to date, and is widely covered by Medicare and many private payers, accounting for over 200 million lives.

About Guardant Health

Guardian health is a leading precision oncology company that aims to help beat cancer on a global scale through its proprietary blood tests, large datasets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient outcomes, and reduce healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially theGuardant360 Unscheduled Liquid Biopsy®, Guardant360 CDx and GuardantOMNI® tests for patients with advanced cancer and Guardant Reveal ™ test for patients with early cancer. These tests are fueling the development of its LUNAR screening program, which aims to meet the needs of asymptomatic people eligible for cancer screening and people at higher risk of developing cancer with early detection.

Forward-looking statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the uses, values, benefits, and potential benefits of Guardant Health’s liquid biopsy testing or analysis, which involve risks and uncertainties. likely to cause actual results to vary. materially in relation to the anticipated results and the expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual results could differ materially from these statements due to a number of factors. These risks and uncertainties, and others that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by forward-looking statements made in this press release, include those discussed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Position and Results of Operations” and elsewhere in its annual report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission, including its quarterly report on Form 10- Q for the period ended March 31, 2021. The forward-looking statements contained in this press release are based on information available to Guardant Health at the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect your ut change in its expectations or any change in the events, conditions or circumstances on which such a statement is based, except as Required by law. These forward-looking statements should not be taken as representing the views of Guardant Health as of any date subsequent to the date of this press release.

The references

  1. CDC Centers for Disease Control and Prevention.,24%25%20of%20all % 20cancer% 20deaths. Accessed online May 24, 2021

  2. Accessed online May 24, 2021

  3. Ahmadzada T, Kao S, Reid G, Boyer M, Mahar A, Cooper WA. An update on predictive biomarkers for treatment selection in non-small cell lung cancer. Journal of Clinical Medicine. 2018; 7 (6): 153.

  4. Pakkala S, Ramalingam, Personalized Lung Cancer Therapy: Hitting a Moving Target. JCI Insight. 2018;3 (15): e120858.

  5. Lindeman NI, Cagle PT, Aisner DL et al. Updated Molecular Testing Guidelines for Selecting Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of lung cancer and the Association for Molecular Pathology. Journal of Thoracic Oncology. March 2018; 13 (3): 323-358. doi: 10.1016 / j.jtho.2017.12.001

  6. Kalemkerian GP, ​​Narula N, Kennedy EB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists / International Association for the Study of Lung Cancer / Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Clinical Oncology. March 20, 2018; 36 (9): 911-919. doi: 10.1200 / JCO.2017.76.7293

  7. Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimization of the diagnostic pathway. Translational research in lung cancer. June 2019; 8 (3): 286-301. doi: 10.21037 / tlcr.2019.04.14

  8. Biernacka A, Tsongalis PD, Peterson JD et al. The potential utility of re-extracting somatic mutation test results: KRAS status in pulmonary adenocarcinoma. Cancer genetics. 2016; 209 (5): 195-198. doi: 10.1016 / j.cancergen.2016.03.001

Source link

]]> 0
Nervous wait for cancer test results grows as shortage of pathology bites Fri, 28 May 2021 03:40:00 +0000

Christchurch patients could wait longer to find out if they have cancer after the number of pathologists in a community lab halved in five months.

Canterbury South Community Laboratories (SCL) recently warned general practitioners and private surgeons of delays in processing tissue test results due to the shortage.

“As of Monday, May 10, we will only have three pathologists available when the workload requires six pathologists,” said a letter from CEO Peter Gootjes and Medical Director Dr. Peter Fitzgerald on May 12.

The company would lose another pathologist in August, the letter said.

* Crown Monitor’s reports on Canterbury Board of Health must be kept under wraps
* Canterbury DHB’s $ 180 million bailout: only CEO can approve new hires
* Under-staffed Christchurch Cancer Department doctors receive coaching to deal with stress

“We expect a backlog to build up with delays in turnaround times.”

Gootjes said the decision by the Canterbury District Health Board (CDHB) not to renew a contract for community laboratory services when it expires in July 2022 resulted in resignations and made it impossible to recruit pathologists.

A pathologist from the United States withdrew his candidacy after learning the contract would end in mid-2022, he said.

In December, the Canterbury Board of Health said community laboratory services would be provided by its own laboratory, Canterbury Health Laboratories (CHL), from July 2022.

CHL has previously provided pathology services to public hospitals in Christchurch.

The decision had exacerbated the national shortage of pathologists, Gootjes said.

The usual timeframe for test results was four to five days, but it could reach over 10 days or more if left unchecked, Gootjes said.

Peter Gootjes, chief executive of Southern Community Laboratories, said a shortage of pathologists will cause test results to be delayed.


Peter Gootjes, chief executive of Southern Community Laboratories, said a shortage of pathologists will cause test results to be delayed.

“It will gradually get worse and potentially have clinical effects, which is why we have informed the referees,” said Gootjes.

He said staff tried to prioritize cases that seemed urgent, but that was not always possible.

“There will be some that don’t seem as urgent and can be, because we just don’t know until we’ve looked at them all.”

Gootjes said the company asked CHL to take over 50 percent of the workload from May 10 because it did not have enough staff to handle it, but was told that CHL could only do 20 percent.

CDHB chief executive Peter Bramley said the CHL had “a full complement” of pathologists and was actively recruiting more.

Southern Community Laboratories in Christchurch has a contract to provide community laboratory testing until mid-2022, but is struggling with a staff shortage.


Southern Community Laboratories in Christchurch has a contract to provide community laboratory testing until mid-2022, but is struggling with a staff shortage.

He said CHL had started handling “some” of Canterbury SCL’s cases and planned to do more “in the near future”. He did not specify what proportion CHL was doing.

The turnaround time for reports from all labs was “constantly monitored” and no concerns had been reported so far, Bramley said.

The president of the Royal Australasian College of Surgeons Aotearoa in New Zealand and Christchurch breast cancer surgeon Phillipa Mercer said local surgeons were very concerned about the situation.

“Biopsies will be done, lumps will be taken… and the result will indicate the next step, and we obviously want to let the patient know.

“They can be reassured because it’s benign, or it tells them that they need additional treatment or surgery, and so delays in this area cause delays for the patient in continuing care. . “

Canterbury Charity Hospital founder and surgeon Phil Bagshaw said staff told him some results are taking longer to get.

The hospital sent biopsies of tissue taken during colonoscopies from polyps on the wall of the intestine to be tested “all the time.”

In many cases, surgeons couldn’t tell if they were benign, malignant, or the type of polyps that could become malignant, he said.

Bowel cancers were generally very slow growing, so a longer wait for test results was unlikely to affect the patient’s result.

However, Bagshaw said the timing of the test results may affect the results of other more aggressive cancers.

Canterbury Health Laboratories is the laboratory operated by Canterbury DHB which will take over work currently outsourced to Canterbury Southern Community Laboratories from July 2022.

John Kirk-Anderson / stuff

Canterbury Health Laboratories is the laboratory operated by Canterbury DHB which will take over work currently outsourced to Canterbury Southern Community Laboratories from July 2022.

Christchurch GP and New Zealand Medical Association representative Vanessa Weenink said GPs need to know if there will be any delays in results, so they can inform patients.

She was not aware of the delays so far.

Association of Salaried Medical Specialists executive director Sarah Dalton said the senior doctors’ union supports setting up in-house community laboratory services, but more funding is needed.

“We expect significant investments in the CHL to ensure facilities and personnel are appropriate.”

Source link

]]> 0